午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >SNDX-5613
SNDX-5613
  • SNDX-5613

SNDX-5613 NEW

Price $67 $98 $163
Package 1mg 2mg 5mg
Min. Order:
Supply Ability: 10g
Update Time: 2025-07-11

Product Details

Product Name: SNDX-5613 CAS No.: 2169919-21-3
Purity: 99.74% Supply Ability: 10g
Release date: 2025/07/11

Product Introduction

Bioactivity

NameSNDX-5613
DescriptionRevumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.
In vitroMETHODS: Primary patient-derived NUP98-r AML cells were treated with Revumenib (SNDX-5613) (2, 46, 125 nM) and cell viability was measured. RESULTS Revumenib inhibited the growth of primary patient-derived NUP98-r AML cells. [3]
In vivoSNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.SNDX-5613 shows in vivo plasma( IC50 : 53 nM) .
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility InformationDMSO : 60 mg/mL (95.11 mM), Sonication is recommended.
KeywordsSNDX-5613 | SNDX5613 | SNDX 5613 | myeloid | MLL | Menin-MLL | Menin | lymphoblastic | Leukemia | Inhibitor | inhibit | HistoneMethyltransferase | Histone Methyltransferase | EpigeneticReaderDomain | Epigenetic Reader Domain | AML | ALL | acute
Inhibitors RelatedMAK-683 hydrochloride | ABBV-744 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | Tazemetostat | Piribedil | Curcumin | EPZ015666 | iso-Azalansta | Naphthol AS-E | MRTX-1719 | Bisdemethoxycurcumin
Related Compound LibrariesMethylation Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$67.00/1mg
VIP5Y
TargetMol Chemicals Inc.
2025-07-11
$1.00/150box
Wuhan Nutra Biotechnology Co.,Ltd
2022-11-19
  • Since: 2011-01-07
  • Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY